S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:COCP

Cocrystal Pharma (COCP) Stock Price, News & Analysis

$1.40
-0.10 (-6.67%)
(As of 03/28/2024 ET)
Today's Range
$1.40
$1.74
50-Day Range
$1.40
$1.63
52-Week Range
$1.33
$3.29
Volume
82,840 shs
Average Volume
12,944 shs
Market Capitalization
$14.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Cocrystal Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
614.3% Upside
$10.00 Price Target
Short Interest
Healthy
0.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Cocrystal Pharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.01) to ($2.19) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.10 out of 5 stars

Medical Sector

360th out of 938 stocks

Pharmaceutical Preparations Industry

171st out of 437 stocks

COCP stock logo

About Cocrystal Pharma Stock (NASDAQ:COCP)

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

COCP Stock Price History

COCP Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Recap: Cocrystal Pharma Q4 Earnings
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Cocrystal Pharma Inc (COCP)
Cocrystal Pharma Inc COCP
Recap: Cocrystal Pharma Q3 Earnings
See More Headlines
Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/29/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:COCP
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+614.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.15 per share
Book Value
$4.87 per share

Miscellaneous

Free Float
7,624,000
Market Cap
$14.24 million
Optionable
Not Optionable
Beta
1.34
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Roger D. Kornberg Ph.D. (Age 77)
    Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
    Comp: $125k
  • Dr. Sam Lee Ph.D. (Age 64)
    Co-Founder, Co-CEO & President
    Comp: $521.38k
  • Mr. James J. Martin CPA (Age 57)
    M.B.A., Co-CEO, CFO & Corporate Secretary
    Comp: $521.38k

COCP Stock Analysis - Frequently Asked Questions

Should I buy or sell Cocrystal Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" COCP shares.
View COCP analyst ratings
or view top-rated stocks.

What is Cocrystal Pharma's stock price target for 2024?

1 brokerages have issued 12 month price targets for Cocrystal Pharma's stock. Their COCP share price targets range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price.
View analysts price targets for COCP
or view top-rated stocks among Wall Street analysts.

How have COCP shares performed in 2024?

Cocrystal Pharma's stock was trading at $1.7222 at the beginning of 2024. Since then, COCP stock has decreased by 18.7% and is now trading at $1.40.
View the best growth stocks for 2024 here
.

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 3,700 shares, a decrease of 31.5% from the February 29th total of 5,400 shares. Based on an average daily trading volume, of 12,900 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's stock are sold short.
View Cocrystal Pharma's Short Interest
.

When is Cocrystal Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our COCP earnings forecast
.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.48) EPS for the quarter, meeting the consensus estimate of ($0.48).

When did Cocrystal Pharma's stock split?

Shares of Cocrystal Pharma reverse split on the morning of Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COCP) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners